Chief Executive Officer Jorge Santos da Silva reported the sale of 150,000 shares of MoonLake Immunotherapeutics (NASDAQ:MLTX) through multiple open-market transactions on April 10, 2026 and April 13, 2026, according to a SEC Form 4 filing.
Metric
Value
Shares sold (direct)
150,000
Transaction value
~$2.8 million
Post-transaction shares (direct)
2,924,893
Post-transaction value (direct ownership)
~$53.9 million
Transaction value based on SEC Form 4 weighted average purchase price ($18.35); post-transaction value based on April 13, 2026 market close price.
How does the size of this transaction compare to Mr. Santos da Silva’s past sales?
This sale of 150,000 shares is above his mean sell-trade size of approximately 107,000 shares, and is his second largest single open-market sale since October 2023.
What proportion of Mr. Santos da Silva’s shareholding was impacted?
The transaction reduced his direct ownership by 4.9%, leaving him with 2,924,893 Common Stock shares.
Did the transaction involve any indirect entities or derivative securities?
No, all shares were sold directly by Mr. Santos da Silva; there were no transactions involving family trusts, LLCs, or options in this filing.
What does this activity imply about remaining capacity for further share sales?
With 2,924,893 shares remaining directly and additional Class A ordinary shares still held, Mr. Santos da Silva maintains substantial sale capacity, and the trade aligns with the cadence established over the last eighteen months.
Metric
Value
Price (as of market close 4/13/26)
$18.43
Market capitalization
$1.35 billion
Net income (TTM)
-$227.32 million
1-year price change
-47.47%
* 1-year performance calculated using April 13th, 2026 as the reference date.
MoonLake Immunotherapeutics is developing Sonelokimab, a novel Nanobody therapy, with current focus on Phase II trials for inflammatory diseases such as hidradenitis suppurativa, psoriatic arthritis, and ankylosing spondylitis.
The company operates as a clinical-stage biopharmaceutical…
..
